EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments

Stefano Fiorucci iD, Ginevra Urbani iD, Cristina Di Giorgio iD, Michele Biagioli iD, Eleonora Distrutti

Cells · 04.10.2024 · 13 (19) · 1650

DOI: 10.3390/cells13191650 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 04.10.2024. Verfasst von Stefano Fiorucci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina e Chirurgia, Università di Perugia, 06123 Perugia, Italy. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Bile Acids and Salts. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sclerosing cholangitis (PSC) is a rare, chronic liver disease with no approved therapies. The ursodeoxycholic acid (UDCA) has been widely used, although there is no evidence that the use of UDCA delays the time to liver transplant or increases survival. Several candidate drugs are currently being developed. The largest group of these new agents is represented by FXR agonists, including obeticholic acid, cilofexor, and tropifexor. Other agents that target bile acid metabolism are ASTB/IBAP inhibitors and fibroblasts growth factor (FGF)19 analogues. Cholangiocytes, the epithelial bile duct cells, play a role in PSC development. Recent studies have revealed that these cells undergo a downregulation of GPBAR1 (TGR5), a bile acid receptor involved in bicarbonate secretion and immune regulation. Additional agents under evaluation are PPARs (elafibranor and seladelpar), anti-itching agents such as MAS-related G-protein–coupled receptors antagonists, and anti-fibrotic and immunosuppressive agents. Drugs targeting gut bacteria and bile acid pathways are also under investigation, given the strong link between PSC and gut microbiota.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingBile Acids and SaltsHumansAnimals

Stichwörter der Autor:innen

GPBAR1 (TGR5)bile acidsbiliary fibrosischolangiocytescholestasisfarnesoid X receptormicrobiotaprimary sclerosing cholangitis

Substanzen

Bile Acids and Salts

Autor:innen und Institutionen

  • Dipartimento di Medicina e Chirurgia, Università di Perugia, 06123 Perugia, Italy.
  • SC di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06123 Perugia, Italy.

ORCID-Profile: Stefano Fiorucci, Ginevra Urbani, Cristina Di Giorgio, Michele Biagioli

Zitieren

APA

Fiorucci, S., Urbani, G., Di Giorgio, C., Biagioli, M., & Distrutti, E. (2024). Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments. Cells, 13(19), 1650. https://doi.org/10.3390/cells13191650

Vancouver

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E. Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments. Cells. 2024;13(19):1650. doi:10.3390/cells13191650

BibTeX
@article{Fiorucci2024,
  author = {Fiorucci, Stefano and Urbani, Ginevra and Di Giorgio, Cristina and Biagioli, Michele and Distrutti, Eleonora},
  title = {Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {19},
  pages = {1650},
  doi = {10.3390/cells13191650}
}
Kostenlos starten →